247 related articles for article (PubMed ID: 21913886)
1. Immunomodulatory properties of thalidomide analogs: pomalidomide and lenalidomide, experimental and therapeutic applications.
Bodera P; Stankiewicz W
Recent Pat Endocr Metab Immune Drug Discov; 2011 Sep; 5(3):192-6. PubMed ID: 21913886
[TBL] [Abstract][Full Text] [Related]
2. Properties of thalidomide and its analogues: implications for anticancer therapy.
Teo SK
AAPS J; 2005 Mar; 7(1):E14-9. PubMed ID: 16146335
[TBL] [Abstract][Full Text] [Related]
3. Pharmacological properties of thalidomide and its analogues.
De Sanctis JB; Mijares M; Suárez A; Compagnone R; Garmendia J; Moreno D; Salazar-Bookaman M
Recent Pat Inflamm Allergy Drug Discov; 2010 Jun; 4(2):144-8. PubMed ID: 20307255
[TBL] [Abstract][Full Text] [Related]
4. The anti-cancer agents lenalidomide and pomalidomide inhibit the proliferation and function of T regulatory cells.
Galustian C; Meyer B; Labarthe MC; Dredge K; Klaschka D; Henry J; Todryk S; Chen R; Muller G; Stirling D; Schafer P; Bartlett JB; Dalgleish AG
Cancer Immunol Immunother; 2009 Jul; 58(7):1033-45. PubMed ID: 19009291
[TBL] [Abstract][Full Text] [Related]
5. Thalidomide analogues as anticancer drugs.
Aragon-Ching JB; Li H; Gardner ER; Figg WD
Recent Pat Anticancer Drug Discov; 2007 Jun; 2(2):167-74. PubMed ID: 17975653
[TBL] [Abstract][Full Text] [Related]
6. Thalidomide analogs as emerging anti-cancer drugs.
Dredge K; Dalgleish AG; Marriott JB
Anticancer Drugs; 2003 Jun; 14(5):331-5. PubMed ID: 12782937
[TBL] [Abstract][Full Text] [Related]
7. The potential of immunomodulatory drugs in the treatment of solid tumors.
Dalgleish A; Galustian C
Future Oncol; 2010 Sep; 6(9):1479-84. PubMed ID: 20919830
[TBL] [Abstract][Full Text] [Related]
8. Lenalidomide - current understanding of mechanistic properties.
Tageja N
Anticancer Agents Med Chem; 2011 Mar; 11(3):315-26. PubMed ID: 21426296
[TBL] [Abstract][Full Text] [Related]
9. Pomalidomide therapy for multiple myeloma and myelofibrosis: an update.
Lacy MQ; Tefferi A
Leuk Lymphoma; 2011 Apr; 52(4):560-6. PubMed ID: 21338284
[TBL] [Abstract][Full Text] [Related]
10. The thalidomide saga.
Melchert M; List A
Int J Biochem Cell Biol; 2007; 39(7-8):1489-99. PubMed ID: 17369076
[TBL] [Abstract][Full Text] [Related]
11. Thalidomide and its analogues have distinct and opposing effects on TNF-alpha and TNFR2 during co-stimulation of both CD4(+) and CD8(+) T cells.
Marriott JB; Clarke IA; Dredge K; Muller G; Stirling D; Dalgleish AG
Clin Exp Immunol; 2002 Oct; 130(1):75-84. PubMed ID: 12296856
[TBL] [Abstract][Full Text] [Related]
12. [Immunomodulatory drugs (IMiDs)].
Oshima K; Ichinohe T
Nihon Rinsho; 2014 Jun; 72(6):1130-5. PubMed ID: 25016816
[TBL] [Abstract][Full Text] [Related]
13. Thalidomide-derived immunomodulatory drugs as therapeutic agents.
Galustian C; Labarthe MC; Bartlett JB; Dalgleish AG
Expert Opin Biol Ther; 2004 Dec; 4(12):1963-70. PubMed ID: 15571458
[TBL] [Abstract][Full Text] [Related]
14. Thalidomide derived immunomodulatory drugs (IMiDs) as potential therapeutic agents.
Marriott JB; Dredge K; Dalgleish AG
Curr Drug Targets Immune Endocr Metabol Disord; 2003 Sep; 3(3):181-6. PubMed ID: 12871024
[TBL] [Abstract][Full Text] [Related]
15. Thalidomide and lenalidomide in the treatment of multiple myeloma.
Kumar S; Rajkumar SV
Eur J Cancer; 2006 Jul; 42(11):1612-22. PubMed ID: 16750621
[TBL] [Abstract][Full Text] [Related]
16. IMiDs: a novel class of immunomodulators.
Knight R
Semin Oncol; 2005 Aug; 32(4 Suppl 5):S24-30. PubMed ID: 16085014
[TBL] [Abstract][Full Text] [Related]
17. Lenalidomide mode of action: linking bench and clinical findings.
Davies F; Baz R
Blood Rev; 2010 Nov; 24 Suppl 1():S13-9. PubMed ID: 21126632
[TBL] [Abstract][Full Text] [Related]
18. Therapeutic effect of the immunomodulatory drug lenalidomide, but not pomalidomide, in experimental models of rheumatoid arthritis and inflammatory bowel disease.
Lopez-Millan B; Diaz de la Guardia R; Roca-Ho H; García-Herrero CM; Lavoie JR; Rosu-Myles M; Gonzalez-Rey E; O'Valle F; Criado G; Delgado M; Menendez P
Exp Mol Med; 2017 Feb; 49(2):e290. PubMed ID: 28154372
[TBL] [Abstract][Full Text] [Related]
19. The evolution of thalidomide and its IMiD derivatives as anticancer agents.
Bartlett JB; Dredge K; Dalgleish AG
Nat Rev Cancer; 2004 Apr; 4(4):314-22. PubMed ID: 15057291
[No Abstract] [Full Text] [Related]
20. Mechanism of action of lenalidomide in hematological malignancies.
Kotla V; Goel S; Nischal S; Heuck C; Vivek K; Das B; Verma A
J Hematol Oncol; 2009 Aug; 2():36. PubMed ID: 19674465
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
